{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:47:51Z","timestamp":1791920871142,"version":"4.3.4"},"reference-count":63,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T00:00:00Z","timestamp":1478736000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health (US)","doi-asserted-by":"crossref","award":["U01 AI84735"],"award-info":[{"award-number":["U01 AI84735"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI106499"],"award-info":[{"award-number":["U01 AI106499"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["TL1 TR001081"],"award-info":[{"award-number":["TL1 TR001081"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR001082"],"award-info":[{"award-number":["UL1 TR001082"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 AI 7447-23"],"award-info":[{"award-number":["T32 AI 7447-23"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0165505","type":"journal-article","created":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T18:40:18Z","timestamp":1478803218000},"page":"e0165505","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Model Linking Plasma and Intracellular Tenofovir\/Emtricitabine with Deoxynucleoside Triphosphates"],"prefix":"10.1371","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5022-3323","authenticated-orcid":true,"given":"Xinhui","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5092-7910","authenticated-orcid":false,"given":"Sharon M.","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose R.","family":"Castillo-Mancilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lane R.","family":"Bushman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Kiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"MaWhinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,11,10]]},"reference":[{"issue":"15","key":"ref1","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2165\/00003495-200363150-00006","article-title":"Tenofovir disoproxil fumarate","volume":"63","author":"T Chapman","year":"2003","journal-title":"Drugs"},{"issue":"9","key":"ref2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","article-title":"Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics","volume":"43","author":"BP Kearney","year":"2004","journal-title":"Clinical pharmacokinetics"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1128\/AAC.40.1.22","article-title":"Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine","volume":"40","author":"L Naesens","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"1\u20132","key":"ref4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ejps.2012.11.007","article-title":"Selectivity of kinases on the activation of tenofovir, an anti-HIV agent","volume":"48","author":"A Varga","year":"2013","journal-title":"Eur J Pharm Sci"},{"key":"ref5","first-page":"e147","article-title":"Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism","volume":"3","author":"K Madrasi","journal-title":"CPT: pharmacometrics & systems pharmacology"},{"issue":"7","key":"ref6","doi-asserted-by":"crossref","first-page":"e40382","DOI":"10.1371\/journal.pone.0040382","article-title":"Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection","volume":"7","author":"S Duwal","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"ref7","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1128\/AAC.05317-11","article-title":"Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients","volume":"55","author":"G Baheti","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/QAD.0b013e32835a9a2d","article-title":"Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults","volume":"27","author":"G Baheti","year":"2013","journal-title":"AIDS"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1128\/AAC.45.10.2733-2739.2001","article-title":"Phase i\/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults","volume":"45","author":"P Barditch-Crovo","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1128\/AAC.49.2.680-684.2005","article-title":"Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers","volume":"49","author":"JA Droste","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/clpt.2008.201","article-title":"Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109)","volume":"85","author":"D Hirt","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/QAI.0b013e3182829bd0","article-title":"Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention","volume":"62","author":"A Jackson","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1517\/17425255.2012.714367","article-title":"Emtricitabine\/tenofovir in the treatment of HIV infection: current PK\/PD evaluation","volume":"8","author":"A Uglietti","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1128\/AAC.02058-13","article-title":"Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients","volume":"58","author":"E Valade","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1128\/AAC.01517-15","article-title":"Emtricitabine seminal plasma and blood plasma population pharmacokinetics in HIV-infected men in the EVARIST ANRS-EP 49 study","volume":"59","author":"E Valade","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"151","key":"ref16","doi-asserted-by":"crossref","first-page":"151ra25","DOI":"10.1126\/scitranslmed.3004006","article-title":"Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men","volume":"4","author":"PL Anderson","year":"2012","journal-title":"Sci Transl Med"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/cid\/civ346","article-title":"Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment","volume":"61","author":"TR Cressey","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1128\/AAC.01441-15","article-title":"Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation","volume":"59","author":"L Dickinson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/QAD.0b013e32833676eb","article-title":"Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients","volume":"24","author":"M Goicoechea","year":"2010","journal-title":"AIDS"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.00910-10","article-title":"Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients","volume":"55","author":"T Hawkins","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/01.qai.0000167155.44980.e8","article-title":"Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens","volume":"39","author":"T Hawkins","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref22","first-page":"27526873","article-title":"Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State","author":"SM Seifert","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"4\u20135","key":"ref23","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ejps.2008.12.010","article-title":"Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape: an example based on zidovudine","volume":"36","author":"M von Kleist","year":"2009","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/jcph.461","article-title":"Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women","volume":"55","author":"RN Burns","year":"2015","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"ref25","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1128\/AAC.49.8.3361-3366.2005","article-title":"Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy","volume":"49","author":"V Jullien","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"e78814","DOI":"10.1371\/journal.pone.0078814","article-title":"Effect of tenofovir on nucleotidases and cytokines in HIV-1 target cells","volume":"8","author":"N Biswas","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/135965350801300608","article-title":"Effect of nucleoside and nucleotide reverse transcriptase inhibitors of HIV on endogenous nucleotide pools","volume":"13","author":"JE Vela","year":"2008","journal-title":"Antivir Ther"},{"issue":"4","key":"ref28","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1128\/AAC.48.4.1089-1095.2004","article-title":"Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir","volume":"48","author":"AS Ray","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"ref29","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1567-5769(03)00076-6","article-title":"Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor\u2014BCX-1777","volume":"3","author":"S Bantia","year":"2003","journal-title":"International immunopharmacology"},{"key":"ref30","article-title":"Analysis of the endogenous deoxynucleoside triphosphate pool in HIV positive and negative individuals receiving tenofovir-emtricitabine","author":"X Chen","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"ref31","article-title":"A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine","author":"ML Cottrell","year":"2016","journal-title":"J Infect Dis"},{"issue":"12","key":"ref32","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1007\/s11095-008-9787-9","article-title":"The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms","volume":"25","author":"S Sahin","year":"2008","journal-title":"Pharm Res"},{"issue":"23","key":"ref33","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection","volume":"373","author":"JM Molina","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jpba.2011.05.039","article-title":"Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS\/MS detection","volume":"56","author":"LR Bushman","year":"2011","journal-title":"J Pharm Biomed Anal"},{"issue":"20\u201321","key":"ref35","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.jchromb.2009.05.029","article-title":"The simultaneous assay of tenofovir and emtricitabine in plasma using LC\/MS\/MS and isotopically labeled internal standards","volume":"877","author":"T Delahunty","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref36","article-title":"Development and validation of an LC-MS\/MS quantitative method for endogenous deoxynucleoside triphosphates in cellular lysate","author":"X Chen","year":"2016","journal-title":"Biomed Chromatogr"},{"issue":"4","key":"ref37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","article-title":"Likelihood based approaches to handling data below the quantification limit using NONMEM VI","volume":"35","author":"JE Ahn","year":"2008","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"ref38","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"SL Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"ref39","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1023\/B:JOPA.0000012998.04442.1f","article-title":"Simultaneous vs. sequential analysis for population PK\/PD data I: best-case performance","volume":"30","author":"L Zhang","year":"2003","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"ref40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1023\/B:JOPA.0000012999.36063.4e","article-title":"Simultaneous vs. sequential analysis for population PK\/PD data II: robustness of methods","volume":"30","author":"L Zhang","year":"2003","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"ref41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0022-3565(25)24269-0","article-title":"Pharmacodynamic model of tolerance: application to nicotine","volume":"244","author":"HC Porchet","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"ref42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF02353781","article-title":"Convergence of direct and indirect pharmacodynamic response models","volume":"23","author":"WJ Jusko","year":"1995","journal-title":"J Pharmacokinet Biopharm"},{"issue":"3","key":"ref43","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1365-2125.1998.00676.x","article-title":"Characteristics of indirect pharmacodynamic models and applications to clinical drug responses","volume":"45","author":"A Sharma","year":"1998","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"ref44","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1021\/js9901155","article-title":"Role of baseline parameters in determining indirect pharmacodynamic responses","volume":"88","author":"YN Sun","year":"1999","journal-title":"J Pharm Sci"},{"issue":"3","key":"ref45","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10928-008-9088-2","article-title":"Approaches to handling pharmacodynamic baseline responses","volume":"35","author":"C Dansirikul","year":"2008","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/bcp.12451","article-title":"Covariate selection in pharmacometric analyses: a review of methods","volume":"79","author":"MM Hutmacher","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"ref47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","article-title":"Xpose\u2014an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM","volume":"58","author":"EN Jonsson","year":"1999","journal-title":"Computer methods and programs in biomedicine"},{"issue":"3","key":"ref48","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/135965350601100302","article-title":"In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine","volume":"11","author":"K Borroto-Esoda","year":"2006","journal-title":"Antivir Ther"},{"issue":"1","key":"ref49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1592\/phco.21.1.11.34439","article-title":"Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians","volume":"21","author":"DS Stein","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"2","key":"ref50","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jac\/dkq447","article-title":"Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection","volume":"66","author":"PL Anderson","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"14","key":"ref51","doi-asserted-by":"crossref","first-page":"7887","DOI":"10.1074\/jbc.271.14.7887","article-title":"Cellular phosphorylation of anti-HIV nucleosides. Role of nucleoside diphosphate kinase","volume":"271","author":"J Bourdais","year":"1996","journal-title":"J Biol Chem"},{"issue":"34","key":"ref52","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.2174\/0929867311320340005","article-title":"The role of soluble 5'-nucleotidases in the conversion of nucleotide analogs: metabolic and therapeutic aspects","volume":"20","author":"AC Skladanowski","year":"2013","journal-title":"Current medicinal chemistry"},{"issue":"6","key":"ref53","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1128\/AAC.06337-11","article-title":"Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine","volume":"56","author":"JE Rower","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"ref54","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1468-1293.2004.00194.x","article-title":"Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial)","volume":"5","author":"JM Molina","year":"2004","journal-title":"HIV medicine"},{"issue":"17","key":"ref55","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2165\/11203800-000000000-00000","article-title":"Efavirenz\/emtricitabine\/tenofovir disoproxil fumarate single-tablet regimen (Atripla(R)): a review of its use in the management of HIV infection","volume":"70","author":"ED Deeks","year":"2010","journal-title":"Drugs"},{"issue":"3","key":"ref56","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/QAI.0b013e318050d88c","article-title":"Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine\/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137","volume":"45","author":"S Ramanathan","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"ref57","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1128\/AAC.50.4.1304-1310.2006","article-title":"Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state","volume":"50","author":"GE Chittick","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"ref58","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/0091270007300951","article-title":"Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers","volume":"47","author":"MR Blum","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"ref59","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1089\/aid.2004.20.1173","article-title":"Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection","volume":"20","author":"LH Wang","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"ref60","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/aid.2012.0089","article-title":"Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure","volume":"29","author":"JR Castillo-Mancilla","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"9","key":"ref61","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1128\/AAC.42.9.2380","article-title":"Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults","volume":"42","author":"SG Deeks","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"ref62","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1128\/AAC.49.5.1907-1914.2005","article-title":"Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients","volume":"49","author":"A Pruvost","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"112","key":"ref63","doi-asserted-by":"crossref","first-page":"112re4","DOI":"10.1126\/scitranslmed.3003174","article-title":"Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission","volume":"3","author":"KB Patterson","year":"2011","journal-title":"Sci Transl Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0165505","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T10:35:13Z","timestamp":1749724513000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0165505"}},"subtitle":[],"editor":[{"given":"Alan","family":"Winston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,11,10]]},"references-count":63,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0165505","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,10]]}}}